The IMID Forum
ACR 2024 Review Podcast
Nov 28, 2024
Key highlights from the ACR 2024 conference on immune-mediated inflammatory diseases are explored, with a focus on findings related to psoriatic arthritis. The potential of JAK inhibitors, like gazelcomab, is discussed alongside insights into the role of sex differences in medication responses. The impact of central nervous system factors on fatigue in inflammatory diseases is also examined. Emerging treatments like Sonolocumab and advancements in rheumatoid arthritis care are covered, while mental health outcomes related to bimicizumab treatment are analyzed.
50:04
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Research highlights gender-specific responses to psoriatic arthritis treatments, with women generally experiencing greater disease activity and different treatment effectiveness, although emerging studies like Guzelcomab challenge these trends.
- New findings from trials indicate that biomarkers related to pain in psoriatic arthritis, especially those identified in Ducravacitinib studies, could pave the way for personalized treatment strategies based on inflammatory responses.
Deep dives
Sex Differences in Psoriatic Arthritis Treatment Responses
Research indicates that male and female patients show differing responses to psoriatic arthritis treatments, particularly regarding biologic agents. A significant meta-analysis revealed that women exhibited greater disease activity and less favorable responses to most treatments, except for JAK inhibitors. A new abstract focused on Guzelcomab concluded that there was no disparity in treatment response between genders, marking a shift in understanding. Ongoing trials, such as the SAGE trial, aim to further analyze sex differentiation in treatment responses by considering factors like hormonal status and immunobiology.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
